Physician profile
Benjamin S Hall
NPI 1851556724
$154,245.77
in general payments reported to CMS, 2019-2025
39 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,462 · 2021: $12K · 2022: $15K · 2023: $16K · 2024: $38K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $85K · Food and Beverage: $11K · Consulting Fee: $2,700 · Travel and Lodging: $501 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,035.66 |
| Food and Beverage | $11,108.22 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $501.43 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45,892.70 | 2019-2025 | |
| Janssen Biotech, INC. | $30,310.68 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $27,546.35 | 2019-2025 | |
| Genzyme Corporation | $22,796.70 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,762.74 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $8,566.65 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $2,613.24 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $1,207.23 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,029.51 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $979.50 | 2019-2025 | Epclusa |
| Aimmune Therapeutics, INC. | $958.08 | 2024 | |
| Celgene Corporation | $514.41 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $509.52 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $380.95 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $316.23 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $312.31 | 2023-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $230.80 | 2020-2024 | Stelara |
| Ferring Pharmaceuticals INC. | $209.49 | 2019-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $205.47 | 2019-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $199.48 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $130.72 | 2019-2024 | Linzess |
| Organon LLC | $104.88 | 2022-2025 | Hadlima |
| Amgen INC. | $77.85 | 2021-2025 | Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.03 | 2023-2024 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $43.53 | 2024-2025 | Iqirvo, Bylvay |
| Ucb, INC. | $40.67 | 2019-2020 | |
| Celltrion USA INC. | $35.60 | 2024-2025 | Zymfentra, Vegzelma |
| Nestle Healthcare Nutrition INC. | $29.21 | 2021-2023 | |
| Covidien Lp | $23.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.17 | 2020-2025 | |
| Alnylam Pharmaceuticals INC. | $21.25 | 2025 | Givlaari |
| Conmed Corporation | $19.44 | 2019 | |
| Exact Sciences Corporation | $17.69 | 2023 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $17.05 | 2022 | |
| Welch Allyn | $16.90 | 2021 | |
| Shire North American Group INC | $15.96 | 2019 | |
| Daiichi Sankyo INC. | $14.99 | 2023 | Injectafer |
| Allergan, INC. | $13.70 | 2019 | |
| Baxter Healthcare | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.